NCT03874338View on ClinicalTrials.gov

CLEAR SYNERGY Neutrophil Substudy

CompletedOBSERVATIONAL
Enrollment

322

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

February 20, 2023

Study Completion Date

August 9, 2024

Conditions
Neutrophils.Hypersegmented | Bld-Ser-PlasSTEMI - ST Elevation Myocardial Infarction
Interventions
DRUG

Colchicine Pill

Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.

Trial Locations (1)

10016

NYU School of Medicine, New York

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

NYU Langone Health

OTHER

NCT03874338 - CLEAR SYNERGY Neutrophil Substudy | Biotech Hunter | Biotech Hunter